Regulus Therapeutics (RGLS)
(Delayed Data from NSDQ)
$1.57 USD
-0.02 (-1.26%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $1.56 -0.01 (-0.64%) 5:30 PM ET
4-Sell of 5 4
F Value D Growth C Momentum F VGM
Brokerage Reports
Regulus Therapeutics Inc. [RGLS]
Reports for Purchase
Showing records 201 - 220 ( 275 total )
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
March and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
March and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Q4/2014 Financials: We Project Cash Runway Through 2016 Next: RG-101 Phase 2 Design; Reiterate OUTPERFORM, Increase PT to $41 for Time Value
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Discontinuation of Coverage of the Biotech Sector
Provider: Brinson Patrick Securities Corporation
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Raising PT on Spectacular 4mg/kg Single Dose Results, in Our View; Reiterate OUTPERFORM and Raising PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Feb 9
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
February and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
2015 Clinical Map Initiative Suggests Aggressive Pipeline Progress and Multiple Value-Drivers; Reiterate OUTPERFORM and $23 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
2015 Clinical Map Initiative Suggests Aggressive Pipeline Progress and Multiple Value-Drivers
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
January and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
ASN Review: RG-012 Demonstrates Robust Efficacy in Preclinical Studies for Alport Syndrome; Reiterate OUTPERFORM and $23 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
ASN Review: RG-012 Demonstrates Robust Efficacy in Preclinical Studies for Alport Syndrome
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Q3 Financials and Pipeline Update; Anticipate Multiple Catalysts in 2015; Reiterate OUTPERFORM and $23 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
November and Remaining 2014 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Financing Provides Flexibility for Pipeline Development & Runway Well Into 2016; Reiterate OUTPERFORM and Increasing PT to $23 for HCV Upside.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
ASN Preview: Preclinical Data Suggest RG012 Could Be a Transformative Treatment for Alport Syndrome; Reiterate OUTPERFORM and $19 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
RG-101 Treatment of HCV Shows Potent and Broad Initial Efficacy
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Preclinical Data at OTS Also Supports Potentially Material Clinical Catalyst in Q4; Reiterate OUTPERFORM and $19 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L